S.C. Ropharma Valuation

Q: What is the Fair Price of RPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RPH (RON0.18) is trading above our estimate of [[fair value]] (RON0.1)

Is RPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RPH (RON0.18) is trading above our estimate of fair value (RON0.1)

Significantly Below Fair Value: RPH is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RPH?

Key metric: As RPH is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RPH. This is calculated by dividing RPH's market cap by their current revenue.
What is RPH's PS Ratio?
PS Ratio	0.08x
Sales	RON 1.19b
Market Cap	RON 90.49m

RPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	7.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RPH's PS Ratio compare to its peers?

The above table shows the PS ratio for RPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.8x
RMAH Farmaceutica REMEDIA	0.08x	n/a	RON 58.9m
CBOT S.C. Comcereal	0.3x	n/a	RON 48.6m
BUCU S.C. Bucur Obor	4.5x	n/a	RON 165.9m
BUCV S.C. Bucur	2.1x	n/a	RON 89.9m
RPH S.C. Ropharma	0.08x	n/a	RON 90.5m

Price-To-Sales vs Peers: RPH is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does RPH's PS Ratio compare vs other companies in the European Consumer Retailing Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	0.3x	4.4%
RPH S.C. Ropharma	0.08x	n/a	US$18.94m

10 Companies		Estimated Growth	Market Cap
Industry Avg.	0.3x	11.3%
RPH S.C. Ropharma	0.08x	n/a	US$18.94m

No more companies

Price-To-Sales vs Industry: RPH is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Consumer Retailing industry average (0.3x).

Price to Sales Ratio vs Fair Ratio

What is RPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.08x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RPH's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.